| Abstrakt: |
Introduction. Research shows the correlation between angiotensin-converting enzyme (ACE) deletion and insertion (D/I) polymorphism and COVID-19 risk; yet, conclusive evidence is still lacking. Thus, a meta-analysis of relevant articles was performed to more accurately estimate the relationship of ACE I/D polymorphism with the risk of COVID-19. Material and Methods. Relevant literature from the PubMed database was systematically reviewed, and odds ratios (ORs) and associated 95% confidence intervals (CIs) were measured. Additionally, the metapackage from Stata version 15.0 was used for statistical analysis. Results. The meta-analysis eventually contained 8 studies, including 1362 COVID-19 cases and 4312 controls. Based on the data, the ACE I/D polymorphism did not show an association with COVID-19 risk (D vs. I: OR = 1.25 , 95% CI = 0.96 – 1.64 ; DD vs. II: OR = 1.89 , 95% CI = 0.95 – 3.74 ; DI vs. II: OR = 1.75 , 95% CI = 0.92 – 3.31 ; dominant model: OR = 1.88 , 95% CI = 0.99 – 3.53 ; and recessive model: OR = 1.24 , 95% CI = 0.81 – 1.90). Further, subgroup analyses stratified based on case proved that the ACE D allele demonstrated an association with increasing risk of COVID-19 severity (D vs. I: OR = 1.64 , 95% CI = 1.01 – 2.66 ; DD vs. II: OR = 4.62 , 95% CI = 2.57 – 8.30 ; DI vs. II: OR = 3.07 , 95% CI = 1.75 – 5.38 ; dominant model: OR = 3.74 , 95% CI = 2.15 – 6.50 ; and recessive model: OR = 1.28 , 95% CI = 0.46 – 3.51). Conclusions. The ACE D allele was clearly related to an enhanced risk of COVID-19 severity. Hence, it is imperative to take into account the influence of genetic factors during the development of future vaccines. [ABSTRACT FROM AUTHOR] |
